calendar
11 catalysts · 18,987 approval · 5,000 device 510k · 4,728 grant · 3,827 phase readout · 2,125 8k filing · 2,000 device pma
11 catalysts · 18,987 approval · 5,000 device 510k · 4,728 grant · 3,827 phase readout · 2,125 8k filing · 2,000 device pma
Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome (Preleukemia)
Therapy area: Oncology. Indication: Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma
Therapy area: Gastrointestinal. Indication: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)
Therapy area: Cardiovascular, Gastrointestinal. Indication: Endothelial Dysfunction, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)
Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Prostate Cancer, Prostate Cancer
Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration
Therapy area: Ophthalmology. Indication: Choroidal Neovascularization
Therapy area: Genetic Disorders. Indication: Duchenne Muscular Dystrophy
Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion
Therapy area: Ophthalmology. Indication: Diabetic Retinopathy
Therapy area: Ophthalmology. Indication: Diabetic Macular Edema